Comparison of diagnostic performance of AFP, DCP and two diagnostic models in hepatocellular carcinoma: a retrospective study

Chen, Yongwu; Yang, Xiuli; Shao, Yanfei; Zhao, Hongying; Jiang, Jialiang; Huang, Ping; Lu, Yi; Xuan, Zixue

doi:10.1016/j.aohep.2023.101099

Cited by 3 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to the aforementioned GALAD score and the algorithms, there are several AFP-integrated protein-based panels still under phase 2 biomarker validation (Table 2 ). For example, using the same variables included in the GALAD score, GALAD-C, 86 87 GAAP, 86 87 116 ASAP, 116 117 118 and AALP 87 models were tailored and validated for HCC detection in Chinese populations. Another approach includes the incorporation of machine-learning models, such as gradient boosting that optimize the combination of AFP, AFP-L3%, and DCP to augment HCC detection.…”

Section: Afp As a Detection/screening Biomarker For Hccmentioning

confidence: 99%

Alpha-fetoprotein: Past, present, and future

Yeo,

Lee,

Tseng

et al. 2024

Hepatology Communications

View full text Add to dashboard Cite

Alpha-fetoprotein (AFP) is a glycoprotein that plays an important role in immune regulation with critical involvement in early human development and maintaining the immune balance during pregnancy. Postfetal development, the regulatory mechanisms controlling AFP undergo a shift and AFP gene transcription is suppressed. Instead, these enhancers refocus their activity to maintain albumin gene transcription throughout adulthood. During the postnatal period, AFP expression can increase in the setting of hepatocyte injury, regeneration, and malignant transformation. It is the first oncoprotein discovered and is routinely used as part of a screening strategy for HCC. AFP has been shown to be a powerful prognostic biomarker, and multiple HCC prognosis models confirmed the independent prognostic utility of AFP. AFP is also a useful predictive biomarker for monitoring the treatment response of HCC. In addition to its role as a biomarker, AFP plays important roles in immune modulation to promote tumorigenesis and thus has been investigated as a therapeutic target in HCC. In this review article, we aim to provide an overview of AFP, encompassing the discovery, biological role, and utility as an HCC biomarker in combination with other biomarkers and how it impacts clinical practice and future direction.

show abstract